Dihydropyrimidinase; DHP; DHPase; Dihydropyrimidine amidohydrolase; Hydantoinase; DPYS

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit Ig

Rabbit

This DPYS antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 454-482 amino acids from the C-terminal region of human DPYS.

Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Vial Concentration: 0.5 (lot specific)

Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C in small aliquots to prevent freeze-thaw cycles.

Small volumes of anti-DPYS antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Dihydropyrimidinase catalyzes the conversion of
5,6-dihydrouracil to 3-ureidopropionate in pyrimidine metabolism.
Dihydropyrimidinase is expressed at a high level in liver and
kidney as a major 2.5-kb transcript and a minor 3.8-kb transcript.
Defects in the DPYS gene are linked to dihydropyrimidinuria.

Western Blot (WB), ELISA (EIA), Immunohistochemistry (IHC)

WB~~1:1000

DPYS Antibody (C-term) western blot analysis in Jurkat,K562 cell line lysates (35ug/lane).This demonstrates the DPYS antibody detected the DPYS protein (arrow).

DPYS Antibody (C-term) immunohistochemistry analysis in formalin fixed and paraffin embedded human kidney tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of DPYS Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.

56630

dihydropyrimidinase

dihydropyrimidinase

Dihydropyrimidinase

DHP; DHPase??[Similar Products]

DPYS_HUMAN

Dihydropyrimidinase catalyzes the conversion of 5,6-dihydrouracil to 3-ureidopropionate in pyrimidine metabolism. Dihydropyrimidinase is expressed at a high level in liver and kidney as a major 2.5-kb transcript and a minor 3.8-kb transcript. Defects in the DPYS gene are linked to dihydropyrimidinuria. [provided by RefSeq, Jul 2008]

DPYS: Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyze the ring opening of 5,6- dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate. Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy. Belongs to the DHOase family. Hydantoinase/dihydropyrimidinase subfamily.

Protein type: EC 3.5.2.2; Cofactor and Vitamin Metabolism - pantothenate and CoA biosynthesis; Other Amino Acids Metabolism - beta-alanine; Nucleotide Metabolism - pyrimidine; Xenobiotic Metabolism - drug metabolism - other enzymes; Hydrolase

Chromosomal Location of Human Ortholog: 8q22

Cellular Component: cytosol

Molecular Function: thymine binding; amino acid binding; dihydropyrimidinase activity; uracil binding; zinc ion binding; phosphoprotein binding

Biological Process: beta-alanine metabolic process; pyrimidine nucleoside catabolic process; pyrimidine base metabolic process; nucleobase, nucleoside and nucleotide metabolic process; uracil catabolic process; thymine catabolic process; pyrimidine base catabolic process; protein homotetramerization

Disease: Dihydropyrimidinase Deficiency

Kim, H.Y., et al. BMB Rep 43(8):547-553(2010)
van Kuilenburg, A.B., et al. Biochim. Biophys. Acta 1802 (7-8), 639-648 (2010) :
Fidlerova, J., et al. Cancer Chemother. Pharmacol. 65(4):661-669(2010)
Thomas, H.R., et al. Pharmacogenet. Genomics 18(1):25-35(2008)
Thomas, H.R., et al. Pharmacogenet. Genomics 17(11):973-987(2007)

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.